Magle Chemoswed Holding Ab - Asset Resilience Ratio
Magle Chemoswed Holding Ab (MAGLE) has an Asset Resilience Ratio of 0.02% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Magle Chemoswed Holding Ab (MAGLE) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2023)
This chart shows how Magle Chemoswed Holding Ab's Asset Resilience Ratio has changed over time. See MAGLE net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Magle Chemoswed Holding Ab's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Magle Chemoswed Holding Ab (MAGLE) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr56.00K | 0.02% |
| Total Liquid Assets | Skr56.00K | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Magle Chemoswed Holding Ab maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Magle Chemoswed Holding Ab Industry Peers by Asset Resilience Ratio
Compare Magle Chemoswed Holding Ab's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Magle Chemoswed Holding Ab (2017–2023)
The table below shows the annual Asset Resilience Ratio data for Magle Chemoswed Holding Ab.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.02% | Skr56.00K ≈ $6.03K |
Skr272.97 Million ≈ $29.38 Million |
+0.24pp |
| 2022-12-31 | -0.22% | Skr-566.00K ≈ $-60.91K |
Skr252.86 Million ≈ $27.21 Million |
+0.01pp |
| 2021-12-31 | -0.24% | Skr-566.00K ≈ $-60.91K |
Skr237.18 Million ≈ $25.52 Million |
-0.29pp |
| 2018-12-31 | 0.05% | Skr75.00K ≈ $8.07K |
Skr152.54 Million ≈ $16.42 Million |
-0.01pp |
| 2017-12-31 | 0.06% | Skr89.00K ≈ $9.58K |
Skr147.88 Million ≈ $15.91 Million |
-- |
About Magle Chemoswed Holding Ab
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride… Read more